CDKN2A and neoplasm: Increased CDK4 activity due to activating mutations, gene amplification, or the inhibition of CDK4-inhibitory signals via the silencing of p16INK4a has been suggested as a tumor-initiating and/or tumor-promoting event in different tumor types.